Moreover, we found no significant differences in PFS or OS between patients with KRAS wt, KRAS G12C, and KRAS non-G12C mutated tumours or among patients with G12C, G12V, G12D, and G12A mutated tumours, which agrees with other studies [2,13,16,24,25,26,27]. Here, KRAS is linked to neoplasm.